Gross Profit Comparison: Taro Pharmaceutical Industries Ltd. and Evotec SE Trends

Taro vs. Evotec: A Decade of Profit Trends

__timestampEvotec SETaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 201429378000580006000
Thursday, January 1, 201537987000676585000
Friday, January 1, 201658554000778966000
Sunday, January 1, 201782568000671251000
Monday, January 1, 2018112016000463508000
Tuesday, January 1, 2019132891000445724000
Wednesday, January 1, 2020125743000399725000
Friday, January 1, 2021151543000296656000
Saturday, January 1, 2022174065000293122000
Sunday, January 1, 2023175051000268323000
Monday, January 1, 2024304979000
Loading chart...

Unleashing insights

A Tale of Two Pharmaceutical Giants: Taro vs. Evotec

In the ever-evolving pharmaceutical industry, Taro Pharmaceutical Industries Ltd. and Evotec SE have showcased intriguing trends over the past decade. From 2014 to 2023, Taro's gross profit has seen a significant decline of approximately 54%, dropping from its peak in 2016. Meanwhile, Evotec has experienced a remarkable growth trajectory, with its gross profit increasing by nearly 500% during the same period. This stark contrast highlights the dynamic nature of the pharmaceutical sector, where strategic decisions and market conditions can lead to vastly different outcomes. Notably, Taro's gross profit in 2023 was about 1.5 times that of Evotec, despite its downward trend. As we look to the future, the missing data for 2024 leaves room for speculation and anticipation. Will Taro regain its former glory, or will Evotec continue its upward climb? Only time will tell.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025